escitalopram orion 15 mg tabletti, suussa hajoava
orion corporation - escitaloprami oxalas - tabletti, suussa hajoava - 15 mg - essitalopraami
escitalopram orion 20 mg tabletti, suussa hajoava
orion corporation - escitaloprami oxalas - tabletti, suussa hajoava - 20 mg - essitalopraami
tetrofosmin rotop 0.23 mg valmisteyhdistelmä radioaktiivista lääkettä varten
rotop pharmaka gmbh - tetrofosmin - valmisteyhdistelmä radioaktiivista lääkettä varten - 0.23 mg - teknetium(99mtc)tetrofosmiini
dasatinib ratiopharm 20 mg tabletti, kalvopäällysteinen
teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 20 mg - dasatinibi
dasatinib ratiopharm 50 mg tabletti, kalvopäällysteinen
teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 50 mg - dasatinibi
dasatinib ratiopharm 70 mg tabletti, kalvopäällysteinen
teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 70 mg - dasatinibi
dasatinib ratiopharm 80 mg tabletti, kalvopäällysteinen
teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 80 mg - dasatinibi
dasatinib ratiopharm 100 mg tabletti, kalvopäällysteinen
teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 100 mg - dasatinibi
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulantit, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.
plerixafor seacross 20 mg/ml injektioneste, liuos
seacross pharma (europe) limited - plerixafor - injektioneste, liuos - 20 mg/ml - pleriksafori